39-43 Brown

nétics for prepackaged emergency contraceptive pills. The application was approved, and the company began marketing the product (under the trade name Preven) in September 1998. This development presumably indicates a more open and positive policy climate for emergency contraception, and the product should lead to standardization of postcoital contraception service delivery at the clinic level. Despite these recent, rapid policy changes, any confusion and reservations about the method’s use that family planning service providers had before the FDA approved emergency contraceptive pills are likely to persist and influence its future dispensation. In this special report, we describe results of a survey conducted in Michigan in October 1996, prior to these policy developments, to assess Title X–funded family planning providers’ attitudes toward and perceptions about the provision of emergency contraception. Results of this survey illuminate obstacles to the provision of postcoital pills and provide insights into how best to integrate this method within the range of Title X reproductive health services.